| Literature DB >> 25610796 |
Zoë A Englander1, Jessica Sun2, Mohamad A Mikati3, Joanne Kurtzberg2, Allen W Song4.
Abstract
Cerebral Palsy (CP) refers to a heterogeneous group of permanent but non-progressive movement disorders caused by injury to the developing fetal or infant brain (Bax et al., 2005). Because of its serious long-term consequences, effective interventions that can help improve motor function, independence, and quality of life are critically needed. Our ongoing longitudinal clinical trial to treat children with CP is specifically designed to meet this challenge. To maximize the potential for functional improvement, all children in this trial received autologous cord blood transfusions (with order randomized with a placebo administration over 2 years) in conjunction with more standard physical and occupational therapies. As a part of this trial, magnetic resonance imaging (MRI) is used to improve our understanding of how these interventions affect brain development, and to develop biomarkers of treatment efficacy. In this report, diffusion tensor imaging (DTI) and subsequent brain connectome analyses were performed in a subset of children enrolled in the clinical trial (n = 17), who all exhibited positive but varying degrees of functional improvement over the first 2-year period of the study. Strong correlations between increases in white matter (WM) connectivity and functional improvement were demonstrated; however no significant relationships between either of these factors with the age of the child at time of enrollment were identified. Thus, our data indicate that increases in brain connectivity reflect improved functional abilities in children with CP. In future work, this potential biomarker can be used to help differentiate the underlying mechanisms of functional improvement, as well as to identify treatments that can best facilitate functional improvement upon un-blinding of the timing of autologous cord blood transfusions at the completion of this study.Entities:
Keywords: Cerebral palsy; Diffusion tensor imaging; GMFM-66; Structural connectome
Mesh:
Year: 2015 PMID: 25610796 PMCID: PMC4297884 DOI: 10.1016/j.nicl.2015.01.002
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.881
Demographic information of the CP patient cohort.
| Subject | Age enrollment | GMFCS level at enrollment | GMFM-66 change over 2 years | Abnormal | Typography |
|---|---|---|---|---|---|
| 1 | 1.7 | IV | 4 | Spasticity with dystonia | Q |
| 2 | 2.4 | II | 8 | Spasticity | D |
| 3 | 5.1 | I | 19 | Spasticity with dystonia | H (Lh) |
| 4 | 1.2 | IV | 4 | Spasticity with dystonia | Q |
| 5 | 4.0 | II | 2 | Spasticity with dystonia | H (Lh) |
| 6 | 4.4 | III | 4 | Spasticity | D |
| 7 | 2.3 | II | 11 | Spasticity | H (Rh) |
| 8 | 1.4 | II | 17 | Spasticity | H (Lh) |
| 9 | 1.1 | I | 16 | Spasticity with dystonia | H (Rh) |
| 10 | 3.7 | II | 11 | Spasticity | H (Rh) |
| 11 | 1.5 | IV | 2 | Spasticity with dystonia | Q |
| 12 | 3.8 | IV | 5 | Spasticity with dystonia | Q |
| 13 | 2.1 | II | 15 | Spasticity | D |
| 14 | 2.8 | II | 13 | Spasticity with dystonia | H (Lh) |
| 15 | 2.8 | II | 5 | Spasticity | D |
| 16 | 1.4 | IV | 6 | Spasticity predominant, mixed with dystonia | Q |
| 17 | 3.0 | III | 22 | Spasticity predominant, mixed with spasticity | T (LUE) |
Q — quadriplegic, D — diplegic, H (Lh) — hemiplegic left hemisphere, H (Rh) — hemiplegic right hemisphere, T (LUE) — tetraplegic left upper extremity.
List of therapies.
| Subject | Therapy (before enrollment) | Therapy (time of enrollment–year 1) | Therapy (year 1–year 2) |
|---|---|---|---|
| 1 | PT initiated at 0–6 months (4 hours/month), | PT/OT/DT/LT (4 hours/month) | PT (8 hours/month), |
| 2 | PT initiated at 12–24 months (2 hours/month), | PT (4 hours/month), OT, LT (1 hour/month), vision, hearing (0.5 hours/month) | PT (2 hours/month), OT/LT/DT/vision/hearing (1 hour/month) |
| 3 | PT initiated >3 years, | PT (2 days/week), | PT (1 day/week), |
| 4 | PT initiated 0–6 months (2 hours/month), | OT (4 hours/month), | PT (16 hours/month) |
| 5 | PT initiated 0–6 months (3 hours/month), | PT (3 hours/month), | OT (1 day/week), |
| 6 | PT initiated 24–36 months (3 days/week), | PT/OT/LT (5 days/week) | PT/OT/LT (3 days/week) |
| 7 | PT initiated 0–6 months (5 hours/month), | PT (7 hours/month), | PT (8 hours/month), |
| 8 | PT initiated 0–6 months (1 day/week), | PT (4 hours/month), OT (4 hours/month), | PT (6 hours/month), |
| 9 | PT initiated 6–12 months (2 hours/month), | OT (4 hours/month) | None |
| 10 | PT initiated 12–24 months (1 hour/month), | PT (4 hours/month), | PT (5 hours/month), |
| 11 | PT initiated 6–12 months (8 hours/month), | PT (4 hours/month), OT (4 hours/month), LT (8 hours/month), vision therapy (8 hours/month), infant school (8 hours/month) | PT (8 hours/month), |
| 12 | PT initiated 0–6 months (4 hours/month), | PT (4 hours/month), | PT (6 hours/month), |
| 13 | PT initiated 12–24 months, (2 hours/month), | PT (1 hour/month), | PT (2 hours/month) |
| 14 | PT initiated 12–24 months (4 hours/month), | PT (4 hours/month), | PT (4 hours/month), OT (4 hours/month), Hippotherapy (4 hours/month) |
| 15 | PT initiated 6–12 months (8 hours/month), | PT (8 hours/month), | PT (4 hours/month) |
| 16 | PT initiated 0–6 months (12 hours/month), | PT (12 hours/month), OT (12 hours/month), LT (6 hours/month), DT (4 hours/month), Hippotherapy (4 hours/month) | PT (10 hours/month), OT (10 hours/month), LT (8 hours/month), Hippotherapy (4 hours/month) |
| 17 | PT initiated 12–24 months (8 hours/month), | PT (12 hours/month), OT (4 hours/month), Hippotherapy (2 hours/month) | PT (12 hours/month), OT (4 hours/month), Hippotherapy (2 hours/month) |
Fig. 1Using whole brain connectome analyses, two measures of brain connectivity change were generated, total connectivity change, reflecting the total increase in connectivity throughout the brain, and sensorimotor connectivity change, reflecting the change in connectivity specifically within the sensorimotor network. Changes in brain connectivity were examined in relation to changes in functional abilities as measured by GMFM-66 score changes. (a) Statistically significant relationships between total connectivity change and GMFM-66 score change (p = 0.020), and (b) sensorimotor connectivity change and GMFM-66 score change (p = 0.035) were observed.
Fig. 4(a) The age of the child at the time of enrollment was not significantly correlated with total (p = 0.944) or (b) sensorimotor connectivity change (p = 0.848).
Fig. 5(a) No relationship between enrollment ages and GMFM-66 score changes was observed in this cohort (p = 0. 979). (b) Children with the most improved functional scores (GMFM-66 score changes > 10) demonstrated significantly higher (p = 0.007) connectivity at the time of enrollment as compared to children who showed more moderate functional improvement over the 2-year period (GMFM-66 score changes < 10). (c) Children with the most improved functional scores demonstrated significantly (p = 0.007) higher FA throughout the brain at time of enrollment than did children who showed more modest functional improvements. (d) Children who showed the greatest functional improvements were classified at lower GMFCS levels at the initial time point (indicating higher levels of gross motor function) than did children who improved more modestly. The group difference in mean GMFCS level was highly significant (p = 0.005).